Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis  

作　　者：Yujing Li Sujun Li Xiaojuan Zhao Jun Sheng Lei Xue Georg Schett Ce Shi Biliang Hu Xingbing Wang Zhu Chen 

机构地区：[1]Department of Rheumatology and Immunology,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China [2]Department of Hematology,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China [3]Department of Rheumatology and Immunology,the First Affiliated Hospital of Wannan Medical College,Wuhu,Anhui,China [4]Department of Internal Medicine 3,Rheumatology and Immunology,Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen,Erlangen,Germany [5]Siweikang Therapeutics,Changsha,Hunan,China [6]Department of Hematology,Centre for Leading Medicine and Advanced Technologies of IHM,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China

出　　处：《Cell Research》2025年第3期220-223,共4页细胞研究(英文版)

基　　金：supported by the National Natural Science Foundation of China(82471819 and 81871227 to Z.C.);Anhui Provincial Health Research Foundation(AHWJ2023A10120 to Z.C.);Anhui Provincial Natural Science Foundation(2408085J046 to Z.C.);Anhui Provincial Key Research and Development Plan(2022h11020009 to Z.C.);the Fundamental Research Funds for the Central Universities(YD9110002012 to Z.C.).

摘　　要：Dear Editor,Rheumatoid arthritis(RA)is an autoimmune inflammatory disease characterized by symmetric synovial inflammation leading to progressive disability.1 Treatment of RA has been revolutionized by the development of monoclonal antibodies against cytokines(e.g.,tumor necrosis factor-α(TNFα)and interleukin-6(IL-6))as well as B-cells(e.g.,CD20-targeted antibody rituximab),resulting in better disease control.2 However,up to 30%of RA patients still escape therapeutic responses despite several cycles of immunomodulatory drugs.3 Such patients are referred to as“difficult-totreat(D2T)”RA according to European Alliance of Associations for Rheumatology(EULAR)definition.3 Here,we report on the efficacy and safety of a new,autologous,fourth-generation CD19-targeted chimeric antigen receptor(CAR)T-cells that secrete antibodies against IL-6 and TNFα(CD19/aIL-6/aTNFα)in treating D2T RA(Fig.1a,b).

关 键 词：chimeric antigen receptor autoimmune inflammatory disease fourth generation t cell therapy treatment resistant tolerable rheumatoid arthritis symmetric synovial inflammation 

分 类 号：R593.22[医药卫生—内科学]